Article Text
Editorial
Thrombolytic therapy for submassive pulmonary embolus? PRO viewpoint
Statistics from Altmetric.com
Footnotes
-
Disclaimer The views expressed in this article do not necessarily represent the personal views or practice of the author, but have been written to stimulate debate.
-
Competing interests Luke Howard has received research funding, speaker fees and fees for consultancy from Bayer.
-
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Pulmonary vasculature
- Pulmonary vasculature
- Editorial
- Airwaves